Altimmune, Inc. — Director's Dealing 2023

Mar 25, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2023-03-24

Reporting Person: Eisenstadt Richard I (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-24	Common Stock, par value $0.0001	P	10000	$4.314	Acquired	22010	Direct